NCT06677489Active, not recruiting
CKD-Heart: Heart Failure Prediction in Asian CKD Patients
Prognostic Modeling of Heart Failure Risk in a Large-Scale Asian Cohort With Chronic Kidney Disease: The CKD-Heart Study
Source: ClinicalTrials.gov · Last updated 15 Apr 2025
Brief summary (registry, in English)
Among patients with known chronic kidney disease (CKD) who are free from diagnosed heart failure (HF), some may be classified as stage A-B HF based on the contemporary 2022 ACC/AHA Guideline for Heart Failure Classification. Several key clinical features and risk factors have been shown to serve as predictors for future HF development. Importantly, compared to white populations, Asians may present with distinct HF risks even when exhibiting the same conventional clinical risk factors for CKD. Our current study aimed to explore the clinical predictors of HF and adverse cardiovascular events among CKD patients in a pre-clinical HF stage (Stage A-B) within a large ethnic Asian population. We further investigated whether baseline characteristics from echocardiography, ECG, and urine protein measurements could provide additional prognostic insights on future events. Addressing this knowledge gap for such a population may facilitate early identification and timely interventions for CKD patients of Asian ethnicity in the early stages of the disease.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- 21 Aug 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Mackay Memorial Hospital
- Diseases
- Chronic kidney disease, Heart failure
- NCT number
- NCT06677489
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 21 Aug 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any terminal disease other than CKD lowering the patient's life expectancy to less than two years
Lab values
- Known impaired LV systolic function (LVEF\<40%) by any imaging modality
- eGFR ≥ 60ml/min/1.73m2
Other
- Known HF hospitalization history
Who the study is looking for
- Clinical diagnosis of CKD (an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m², persisting for 3 months or more)
- Age ≥ 20 years
- Free at baseline of diagnosed HF
- Baseline patient-level clinical data available
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MacKay Memorial Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.